logo

Drug Development

Share SHARE

Merck (MRK) said that it has accepted the external Data Monitoring Committee recommendation to pause new enrollment on KEYNOTE-183 and KEYNOTE-185, two studies exploring KEYTRUDA treatment in combination with other therapies in the blood cancer multiple myeloma. The company noted that the pause is...

The number of drug resistant cases of gonorrhea have increased in the U.S. in recent years, according to a new study from researchers at the Centers for Disease Control and Prevention. The agency released an official statement earlier this week noting that "the future of current treatment options may be in jeopardy."

Pharma-070516.jpg French nanomedicine company Nanobiotix SA (NANO.PA) has reported successful results from its phase I/II trial of its lead product, NBTXR3, in head and neck cancer.

Follow RTT